Guidance in topic selection
Showing 1 to 2 of 2
Title | Technology type | Decision | Decision date |
---|---|---|---|
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969] | Medicine | Not selected | |
MMprofiler for prognostic risk classification in multiple myeloma (MT623) (MIB270) | Diagnostic | Not selected |